SCYNEXIS (135A) Price & Analysis

Compare

1 Followers

135A Stock Chart & Stats

€0.64

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.64

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.48 - €1.11

Previous CloseN/A

Volume0.00

Average Volume (3M)268.00

Market Cap

€28.65M

Enterprise Value€20.02M

Total Cash (Recent Filing)€38.01M

Total Debt (Recent Filing)€2.28M

Price to Earnings (P/E)―

Beta0.17

Next Earnings

Apr 01, 2026

EPS Estimate

0.11

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.14

Shares Outstanding41,965,057

10 Day Avg. Volume125

30 Day Avg. Volume268

Financial Highlights & Ratios

PEG Ratio0.02

Price to Book (P/B)1.07

Price to Sales (P/S)15.67

P/FCF Ratio-2.44

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Development PipelinePositive Phase 1 safety and pharmacokinetic results underpin advancement of SCY-247 into a Phase 2 study for invasive candidiasis, highlighting a next-generation oral and IV antifungal designed for improved tissue penetration and gastrointestinal tolerability.

Financial PositionResolution with GSK provided a $22 million payment that extends Scynexis's cash runway and supports funding of development programs including SCY-247.

Partnership And Commercial MilestonesThe Brexafemme relaunch with GSK makes Scynexis eligible for up to $146 million in annual sales milestones plus low- to mid-single-digit royalties, creating potential material revenue upside if adoption increases.

Bears Say

SCYNEXIS News

Scynexis announces presentation highlighting data from SCY-247

Scynexis (SCYX) announced upcoming presentations highlighting data on the Company’s second-generation fungerp drug candidate, SCY-247, at the inaugural...

16d ago

SCYX

Scynexis receives U.S. FDA QIDP, Fast Track Designations for SCY-247

Scynexis (SCYX) announced that the U.S. Food and Drug Administration, FDA, has granted the Company Qualified Infectious Disease...

23d ago

SCYX

Scynexis granted 180-day extension by Nasdaq to regain compliance

SCYNEXIS (SCYX) announced that it has received an additional 180-calendar-day extension from the Nasdaq Stock Market to regain...

2M ago

SCYX

SCYNEXIS Halts Phase 3 MARIO Trial, Raising New Questions for Ibrexafungerp’s Growth Path

SCYNEXIS Inc ($SCYX) announced an update on their ongoing clinical study. Study Overview: SCYNEXIS Inc. (SCYX) is running...

2M ago

SCYX

Scynexis completes transfer of BREXAFEMME NDA to GSK

SCYNEXIS (SCYX) announced that it has completed the transfer of the BREXAFEMME New Drug Application, NDA, to GSK...

3M ago

GSK

SCYX

Scynexis announces grant for Hackensack Meridian, Johns Hopkins collaboration

SCYNEXIS (SCYX) announced that a novel series of antifungal compounds utilizing SCYNEXIS’ proprietary triterpenoid antifungal platform are among...

3M ago

SCYX

SCYNEXIS: Strong Financial Position and Promising Antifungal Pipeline Drive Buy Rating

SCYNEXIS, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Jason McCarthy from Maxim...

3M ago

SCYX

SCYNEXIS Reports Q3 2025 Financial Results and Strategic Updates

SCYNEXIS Inc ( ($SCYX) ) has released its Q3 earnings. Here is a breakdown of the information SCYNEXIS...

3M ago

SCYX

Scynexis reports Q3 EPS (17c), consensus (20c)

Reports Q3 revenue $334,000, consensus $147,670. “Over the last several weeks, SCYNEXIS (SCYX) realized two significant achievements that...

3M ago

SCYX

SCYX Upcoming Earnings Report: What to Expect?

SCYNEXIS Inc (SCYX) is scheduled to report 3rd quarter earnings on 11/05/2025. Regarding Q3 estimates, Wall Street analysts...

3M ago

SCYX

Scynexis price target lowered to $3 from $4 at Guggenheim

Guggenheim lowered the firm’s price target on Scynexis (SCYX) to $3 from $4 and keeps a Buy rating...

4M ago

GSK

SCYX

SCYNEXIS: Strategic Advancements and Financial Stability Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on SCYNEXIS. The associated price target remains...

4M ago

SCYX

SCYNEXIS and GSK Amend License Agreement

SCYNEXIS ( ($SCYX) ) has shared an update. On October 14, 2025, SCYNEXIS and GSK signed a binding...

4M ago

SCYX

Scynexis, GSK resolve disagreement related to restart of Phase 3 MARIO study

SCYNEXIS (SCYX) announced that it will receive a $22 million payment from GlaxoSmithKline Intellectual Property as part of...

4M ago

SCYX

135A FAQ

What was SCYNEXIS Inc’s price range in the past 12 months?

SCYNEXIS Inc lowest stock price was €0.48 and its highest was €1.11 in the past 12 months.

What is SCYNEXIS Inc’s market cap?

SCYNEXIS Inc’s market cap is €28.65M.

When is SCYNEXIS Inc’s upcoming earnings report date?

SCYNEXIS Inc’s upcoming earnings report date is Apr 01, 2026 which is in 47 days.

How were SCYNEXIS Inc’s earnings last quarter?

SCYNEXIS Inc released its earnings results on Nov 05, 2025. The company reported -€0.143 earnings per share for the quarter, beating the consensus estimate of -€0.168 by €0.025.

Is SCYNEXIS Inc overvalued?

According to Wall Street analysts SCYNEXIS Inc’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does SCYNEXIS Inc pay dividends?

SCYNEXIS Inc does not currently pay dividends.

What is SCYNEXIS Inc’s EPS estimate?

SCYNEXIS Inc’s EPS estimate is 0.11.

How many shares outstanding does SCYNEXIS Inc have?

SCYNEXIS Inc has 41,965,057 shares outstanding.

What happened to SCYNEXIS Inc’s price movement after its last earnings report?

SCYNEXIS Inc reported an EPS of -€0.143 in its last earnings report, beating expectations of -€0.168. Following the earnings report the stock price went down -5.515%.

Which hedge fund is a major shareholder of SCYNEXIS Inc?

Currently, no hedge funds are holding shares in DE:135A

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

SCYNEXIS Stock Smart Score

Neutral

Technicals

Fundamentals

Return on Equity

-53.29%

Trailing 12-Months

Asset Growth

-48.43%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

SCYNEXIS Inc

SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of various fungal infections, including recurrent VVC, invasive aspergillosis, invasive candidiasis, and refractory invasive fungal infections; and ibrexafungerp that has completed Phase 3 CANDLE study for the prevention of recurrent (VVC). It has research collaborations with Merck Sharp & Dohme Corp., Hansoh (Shanghai) Health Technology Co., Ltd., Jiangsu Hansoh Pharmaceutical Group Company Limited, and R-Pharm, CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation, Inc. and changed its name to SCYNEXIS, Inc. in June 2002. SCYNEXIS, Inc. was incorporated in 1999 and is headquartered in Jersey City, New Jersey.